NuVasive, Inc.
NuVasive, Inc. NUVA Peers
See (NUVA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUVA | $39.75 | -2.24% | 2.1B | 75.00 | $0.53 | N/A |
| ABT | $125.73 | +1.05% | 218.7B | 15.79 | $7.96 | +1.86% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $103.16 | -0.60% | 152.6B | 75.31 | $1.37 | N/A |
| SYK | $395.15 | +2.02% | 151.1B | 53.42 | $7.40 | +0.84% |
| MDT | $91.65 | +2.17% | 117.4B | 25.39 | $3.61 | +3.07% |
| EW | $76.30 | -0.33% | 44.8B | 31.53 | $2.42 | N/A |
| DXCM | $85.12 | +1.30% | 33.4B | 64.00 | $1.33 | N/A |
| PHG | $25.02 | +1.96% | 23.1B | 83.37 | $0.30 | +3.55% |
| STE | $223.69 | +0.47% | 22B | 36.30 | $6.16 | +1.02% |
Stock Comparison
NUVA vs ABT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ABT has a market cap of 218.7B. Regarding current trading prices, NUVA is priced at $39.75, while ABT trades at $125.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ABT's P/E ratio is 15.79. In terms of profitability, NUVA's ROE is +0.05%, compared to ABT's ROE of +0.32%. Regarding short-term risk, NUVA is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs BSX-PA Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NUVA is priced at $39.75, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NUVA's ROE is +0.05%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs BSX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSX has a market cap of 152.6B. Regarding current trading prices, NUVA is priced at $39.75, while BSX trades at $103.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSX's P/E ratio is 75.31. In terms of profitability, NUVA's ROE is +0.05%, compared to BSX's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs SYK Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SYK has a market cap of 151.1B. Regarding current trading prices, NUVA is priced at $39.75, while SYK trades at $395.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SYK's P/E ratio is 53.42. In terms of profitability, NUVA's ROE is +0.05%, compared to SYK's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs MDT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MDT has a market cap of 117.4B. Regarding current trading prices, NUVA is priced at $39.75, while MDT trades at $91.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MDT's P/E ratio is 25.39. In terms of profitability, NUVA's ROE is +0.05%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs EW Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, EW has a market cap of 44.8B. Regarding current trading prices, NUVA is priced at $39.75, while EW trades at $76.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas EW's P/E ratio is 31.53. In terms of profitability, NUVA's ROE is +0.05%, compared to EW's ROE of +0.49%. Regarding short-term risk, NUVA is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs DXCM Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, DXCM has a market cap of 33.4B. Regarding current trading prices, NUVA is priced at $39.75, while DXCM trades at $85.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas DXCM's P/E ratio is 64.00. In terms of profitability, NUVA's ROE is +0.05%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, NUVA is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs PHG Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PHG has a market cap of 23.1B. Regarding current trading prices, NUVA is priced at $39.75, while PHG trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PHG's P/E ratio is 83.37. In terms of profitability, NUVA's ROE is +0.05%, compared to PHG's ROE of +0.03%. Regarding short-term risk, NUVA is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs STE Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, STE has a market cap of 22B. Regarding current trading prices, NUVA is priced at $39.75, while STE trades at $223.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas STE's P/E ratio is 36.30. In terms of profitability, NUVA's ROE is +0.05%, compared to STE's ROE of +0.09%. Regarding short-term risk, NUVA is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs PODD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PODD has a market cap of 20.1B. Regarding current trading prices, NUVA is priced at $39.75, while PODD trades at $285.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PODD's P/E ratio is 52.02. In terms of profitability, NUVA's ROE is +0.05%, compared to PODD's ROE of +0.35%. Regarding short-term risk, NUVA is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs ZBH Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ZBH has a market cap of 19.1B. Regarding current trading prices, NUVA is priced at $39.75, while ZBH trades at $96.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ZBH's P/E ratio is 21.45. In terms of profitability, NUVA's ROE is +0.05%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, NUVA is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs ABMD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NUVA is priced at $39.75, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NUVA's ROE is +0.05%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs ALGN Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ALGN has a market cap of 14.1B. Regarding current trading prices, NUVA is priced at $39.75, while ALGN trades at $194.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ALGN's P/E ratio is 35.29. In terms of profitability, NUVA's ROE is +0.05%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs SNN Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SNN has a market cap of 13.5B. Regarding current trading prices, NUVA is priced at $39.75, while SNN trades at $30.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SNN's P/E ratio is 32.91. In terms of profitability, NUVA's ROE is +0.05%, compared to SNN's ROE of +0.08%. Regarding short-term risk, NUVA is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs SWAV Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NUVA is priced at $39.75, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NUVA's ROE is +0.05%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, NUVA is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs PEN Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PEN has a market cap of 9B. Regarding current trading prices, NUVA is priced at $39.75, while PEN trades at $231.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PEN's P/E ratio is 214.84. In terms of profitability, NUVA's ROE is +0.05%, compared to PEN's ROE of +0.04%. Regarding short-term risk, NUVA is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs GMED Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, GMED has a market cap of 7.2B. Regarding current trading prices, NUVA is priced at $39.75, while GMED trades at $53.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas GMED's P/E ratio is 39.27. In terms of profitability, NUVA's ROE is +0.05%, compared to GMED's ROE of +0.05%. Regarding short-term risk, NUVA is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs BIO-B Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BIO-B has a market cap of 7B. Regarding current trading prices, NUVA is priced at $39.75, while BIO-B trades at $257.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BIO-B's P/E ratio is -3.37. In terms of profitability, NUVA's ROE is +0.05%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, NUVA is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs BIO Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BIO has a market cap of 6.7B. Regarding current trading prices, NUVA is priced at $39.75, while BIO trades at $245.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BIO's P/E ratio is -3.21. In terms of profitability, NUVA's ROE is +0.05%, compared to BIO's ROE of -0.32%. Regarding short-term risk, NUVA is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs BRKR Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BRKR has a market cap of 5.9B. Regarding current trading prices, NUVA is priced at $39.75, while BRKR trades at $38.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BRKR's P/E ratio is 74.65. In terms of profitability, NUVA's ROE is +0.05%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, NUVA is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs GKOS Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, GKOS has a market cap of 5.5B. Regarding current trading prices, NUVA is priced at $39.75, while GKOS trades at $96.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas GKOS's P/E ratio is -42.48. In terms of profitability, NUVA's ROE is +0.05%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, NUVA is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs NARI Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NUVA is priced at $39.75, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NARI's P/E ratio is -59.24. In terms of profitability, NUVA's ROE is +0.05%, compared to NARI's ROE of -0.18%. Regarding short-term risk, NUVA is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs IRTC Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IRTC has a market cap of 4.3B. Regarding current trading prices, NUVA is priced at $39.75, while IRTC trades at $133.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IRTC's P/E ratio is -42.48. In terms of profitability, NUVA's ROE is +0.05%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, NUVA is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs ITGR Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ITGR has a market cap of 4B. Regarding current trading prices, NUVA is priced at $39.75, while ITGR trades at $114.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ITGR's P/E ratio is 53.19. In terms of profitability, NUVA's ROE is +0.05%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, NUVA is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs INSP Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, NUVA is priced at $39.75, while INSP trades at $129.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INSP's P/E ratio is 59.06. In terms of profitability, NUVA's ROE is +0.05%, compared to INSP's ROE of +0.10%. Regarding short-term risk, NUVA is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs AXNX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NUVA is priced at $39.75, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NUVA's ROE is +0.05%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NUVA is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs TMDX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TMDX has a market cap of 3.6B. Regarding current trading prices, NUVA is priced at $39.75, while TMDX trades at $105.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TMDX's P/E ratio is 74.37. In terms of profitability, NUVA's ROE is +0.05%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, NUVA is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs PRCT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PRCT has a market cap of 3.3B. Regarding current trading prices, NUVA is priced at $39.75, while PRCT trades at $58.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PRCT's P/E ratio is -34.77. In terms of profitability, NUVA's ROE is +0.05%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NUVA is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs LIVN Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LIVN has a market cap of 2.4B. Regarding current trading prices, NUVA is priced at $39.75, while LIVN trades at $43.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LIVN's P/E ratio is -10.70. In terms of profitability, NUVA's ROE is +0.05%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, NUVA is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs UFPT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, NUVA is priced at $39.75, while UFPT trades at $231.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas UFPT's P/E ratio is 28.32. In terms of profitability, NUVA's ROE is +0.05%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, NUVA is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs SSII Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SSII has a market cap of 1.6B. Regarding current trading prices, NUVA is priced at $39.75, while SSII trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SSII's P/E ratio is -105.62. In terms of profitability, NUVA's ROE is +0.05%, compared to SSII's ROE of -1.05%. Regarding short-term risk, NUVA is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs ATEC Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, NUVA is priced at $39.75, while ATEC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ATEC's P/E ratio is -9.42. In terms of profitability, NUVA's ROE is +0.05%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, NUVA is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs CNMD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, NUVA is priced at $39.75, while CNMD trades at $48.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CNMD's P/E ratio is 12.54. In terms of profitability, NUVA's ROE is +0.05%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, NUVA is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs AORT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, NUVA is priced at $39.75, while AORT trades at $30.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AORT's P/E ratio is -59.57. In terms of profitability, NUVA's ROE is +0.05%, compared to AORT's ROE of -0.07%. Regarding short-term risk, NUVA is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs HSKA Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NUVA is priced at $39.75, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NUVA's ROE is +0.05%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NUVA is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs AHCO Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, NUVA is priced at $39.75, while AHCO trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AHCO's P/E ratio is 16.34. In terms of profitability, NUVA's ROE is +0.05%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, NUVA is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs ESTA Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ESTA has a market cap of 1.3B. Regarding current trading prices, NUVA is priced at $39.75, while ESTA trades at $43.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ESTA's P/E ratio is -13.93. In terms of profitability, NUVA's ROE is +0.05%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, NUVA is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs SILK Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SILK's P/E ratio is -18.96. In terms of profitability, NUVA's ROE is +0.05%, compared to SILK's ROE of -0.29%. Regarding short-term risk, NUVA is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs FNA Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas FNA's P/E ratio is -19.83. In terms of profitability, NUVA's ROE is +0.05%, compared to FNA's ROE of -0.36%. Regarding short-term risk, NUVA is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs TNDM Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, NUVA is priced at $39.75, while TNDM trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TNDM's P/E ratio is -5.49. In terms of profitability, NUVA's ROE is +0.05%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, NUVA is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs INMD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INMD has a market cap of 1B. Regarding current trading prices, NUVA is priced at $39.75, while INMD trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INMD's P/E ratio is 6.46. In terms of profitability, NUVA's ROE is +0.05%, compared to INMD's ROE of +0.25%. Regarding short-term risk, NUVA is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs IART Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IART has a market cap of 936.4M. Regarding current trading prices, NUVA is priced at $39.75, while IART trades at $12.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IART's P/E ratio is -31.71. In terms of profitability, NUVA's ROE is +0.05%, compared to IART's ROE of -0.03%. Regarding short-term risk, NUVA is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs CSII Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NUVA is priced at $39.75, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CSII's P/E ratio is -20.83. In terms of profitability, NUVA's ROE is +0.05%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NUVA is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs SIBN Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SIBN has a market cap of 731.3M. Regarding current trading prices, NUVA is priced at $39.75, while SIBN trades at $17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SIBN's P/E ratio is -27.24. In terms of profitability, NUVA's ROE is +0.05%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, NUVA and SIBN have similar daily volatility (3.60).
NUVA vs CRY Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, NUVA is priced at $39.75, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CRY's P/E ratio is 425.71. In terms of profitability, NUVA's ROE is +0.05%, compared to CRY's ROE of -0.07%. Regarding short-term risk, NUVA is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs IRMD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IRMD has a market cap of 715.9M. Regarding current trading prices, NUVA is priced at $39.75, while IRMD trades at $56.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IRMD's P/E ratio is 36.32. In terms of profitability, NUVA's ROE is +0.05%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, NUVA is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs APEN Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NUVA is priced at $39.75, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas APEN's P/E ratio is -9.43. In terms of profitability, NUVA's ROE is +0.05%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NUVA is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs BFLY-WT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BFLY-WT has a market cap of 573.6M. Regarding current trading prices, NUVA is priced at $39.75, while BFLY-WT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, NUVA is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs AXGN Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AXGN has a market cap of 571.1M. Regarding current trading prices, NUVA is priced at $39.75, while AXGN trades at $12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AXGN's P/E ratio is -78.37. In terms of profitability, NUVA's ROE is +0.05%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, NUVA is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs KIDS Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, KIDS has a market cap of 563.7M. Regarding current trading prices, NUVA is priced at $39.75, while KIDS trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas KIDS's P/E ratio is -12.93. In terms of profitability, NUVA's ROE is +0.05%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NUVA is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs CBLL Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CBLL has a market cap of 560.9M. Regarding current trading prices, NUVA is priced at $39.75, while CBLL trades at $15.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CBLL's P/E ratio is -12.52. In terms of profitability, NUVA's ROE is +0.05%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, NUVA is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs SMLR Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SMLR has a market cap of 554.2M. Regarding current trading prices, NUVA is priced at $39.75, while SMLR trades at $40.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SMLR's P/E ratio is -16.82. In terms of profitability, NUVA's ROE is +0.05%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, NUVA is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs AVNS Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AVNS has a market cap of 547.5M. Regarding current trading prices, NUVA is priced at $39.75, while AVNS trades at $11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AVNS's P/E ratio is -1.43. In terms of profitability, NUVA's ROE is +0.05%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, NUVA is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs ZIMV Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ZIMV has a market cap of 523M. Regarding current trading prices, NUVA is priced at $39.75, while ZIMV trades at $18.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ZIMV's P/E ratio is -20.81. In terms of profitability, NUVA's ROE is +0.05%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, NUVA is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs PACB Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PACB has a market cap of 486.1M. Regarding current trading prices, NUVA is priced at $39.75, while PACB trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PACB's P/E ratio is -0.59. In terms of profitability, NUVA's ROE is +0.05%, compared to PACB's ROE of -1.70%. Regarding short-term risk, NUVA is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs BFLY Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BFLY has a market cap of 469.8M. Regarding current trading prices, NUVA is priced at $39.75, while BFLY trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BFLY's P/E ratio is -6.33. In terms of profitability, NUVA's ROE is +0.05%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, NUVA is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs SRDX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SRDX has a market cap of 456.2M. Regarding current trading prices, NUVA is priced at $39.75, while SRDX trades at $31.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SRDX's P/E ratio is -22.79. In terms of profitability, NUVA's ROE is +0.05%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, NUVA is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs SENS Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SENS has a market cap of 444.9M. Regarding current trading prices, NUVA is priced at $39.75, while SENS trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SENS's P/E ratio is -5.36. In terms of profitability, NUVA's ROE is +0.05%, compared to SENS's ROE of -7.46%. Regarding short-term risk, NUVA is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs OFIX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, OFIX has a market cap of 434.9M. Regarding current trading prices, NUVA is priced at $39.75, while OFIX trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas OFIX's P/E ratio is -3.00. In terms of profitability, NUVA's ROE is +0.05%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, NUVA is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs BVS Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BVS has a market cap of 427.3M. Regarding current trading prices, NUVA is priced at $39.75, while BVS trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BVS's P/E ratio is -13.42. In terms of profitability, NUVA's ROE is +0.05%, compared to BVS's ROE of -0.21%. Regarding short-term risk, NUVA is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs CTKB Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CTKB has a market cap of 411.6M. Regarding current trading prices, NUVA is priced at $39.75, while CTKB trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CTKB's P/E ratio is -36.11. In terms of profitability, NUVA's ROE is +0.05%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, NUVA is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs TMCI Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TMCI has a market cap of 370.5M. Regarding current trading prices, NUVA is priced at $39.75, while TMCI trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TMCI's P/E ratio is -6.93. In terms of profitability, NUVA's ROE is +0.05%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, NUVA is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs NNOX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NNOX has a market cap of 348.8M. Regarding current trading prices, NUVA is priced at $39.75, while NNOX trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NNOX's P/E ratio is -6.01. In terms of profitability, NUVA's ROE is +0.05%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, NUVA is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs OM Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, OM has a market cap of 335.8M. Regarding current trading prices, NUVA is priced at $39.75, while OM trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas OM's P/E ratio is -0.66. In terms of profitability, NUVA's ROE is +0.05%, compared to OM's ROE of -1.45%. Regarding short-term risk, NUVA is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs PTHL Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PTHL has a market cap of 320.6M. Regarding current trading prices, NUVA is priced at $39.75, while PTHL trades at $22.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PTHL's P/E ratio is -450.00. In terms of profitability, NUVA's ROE is +0.05%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, NUVA is more volatile compared to PTHL. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs CATX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CATX has a market cap of 318.8M. Regarding current trading prices, NUVA is priced at $39.75, while CATX trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CATX's P/E ratio is -3.41. In terms of profitability, NUVA's ROE is +0.05%, compared to CATX's ROE of -0.27%. Regarding short-term risk, NUVA is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs CLPT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CLPT has a market cap of 317.4M. Regarding current trading prices, NUVA is priced at $39.75, while CLPT trades at $11.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CLPT's P/E ratio is -14.78. In terms of profitability, NUVA's ROE is +0.05%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, NUVA is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs VREX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, VREX has a market cap of 314.6M. Regarding current trading prices, NUVA is priced at $39.75, while VREX trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas VREX's P/E ratio is -7.36. In terms of profitability, NUVA's ROE is +0.05%, compared to VREX's ROE of -0.08%. Regarding short-term risk, NUVA is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs NPCE Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NPCE has a market cap of 306.7M. Regarding current trading prices, NUVA is priced at $39.75, while NPCE trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NPCE's P/E ratio is -11.40. In terms of profitability, NUVA's ROE is +0.05%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, NUVA is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs SNWV Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SNWV has a market cap of 302.9M. Regarding current trading prices, NUVA is priced at $39.75, while SNWV trades at $35.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SNWV's P/E ratio is -5.67. In terms of profitability, NUVA's ROE is +0.05%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, NUVA is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs RXST Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RXST has a market cap of 295M. Regarding current trading prices, NUVA is priced at $39.75, while RXST trades at $7.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RXST's P/E ratio is -11.00. In terms of profitability, NUVA's ROE is +0.05%, compared to RXST's ROE of -0.10%. Regarding short-term risk, NUVA is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs CERS Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CERS has a market cap of 274.3M. Regarding current trading prices, NUVA is priced at $39.75, while CERS trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CERS's P/E ratio is -14.35. In terms of profitability, NUVA's ROE is +0.05%, compared to CERS's ROE of -0.35%. Regarding short-term risk, NUVA is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs QTRX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, QTRX has a market cap of 257.1M. Regarding current trading prices, NUVA is priced at $39.75, while QTRX trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas QTRX's P/E ratio is -4.44. In terms of profitability, NUVA's ROE is +0.05%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, NUVA is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs VMD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, VMD has a market cap of 256.9M. Regarding current trading prices, NUVA is priced at $39.75, while VMD trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas VMD's P/E ratio is 20.97. In terms of profitability, NUVA's ROE is +0.05%, compared to VMD's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs MASS Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MASS has a market cap of 253.2M. Regarding current trading prices, NUVA is priced at $39.75, while MASS trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MASS's P/E ratio is -3.18. In terms of profitability, NUVA's ROE is +0.05%, compared to MASS's ROE of -0.13%. Regarding short-term risk, NUVA is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs MXCT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MXCT has a market cap of 238.2M. Regarding current trading prices, NUVA is priced at $39.75, while MXCT trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MXCT's P/E ratio is -5.60. In terms of profitability, NUVA's ROE is +0.05%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, NUVA is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs TCMD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TCMD has a market cap of 232.3M. Regarding current trading prices, NUVA is priced at $39.75, while TCMD trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TCMD's P/E ratio is 15.14. In terms of profitability, NUVA's ROE is +0.05%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, NUVA is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs BWAY Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BWAY has a market cap of 228.7M. Regarding current trading prices, NUVA is priced at $39.75, while BWAY trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BWAY's P/E ratio is 55.00. In terms of profitability, NUVA's ROE is +0.05%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, NUVA is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs NVRO Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NUVA is priced at $39.75, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NUVA's ROE is +0.05%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NUVA is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs CVRX Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CVRX has a market cap of 210.4M. Regarding current trading prices, NUVA is priced at $39.75, while CVRX trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CVRX's P/E ratio is -3.77. In terms of profitability, NUVA's ROE is +0.05%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, NUVA is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs EYES Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, NUVA is priced at $39.75, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas EYES's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to EYES's ROE of -0.26%. Regarding short-term risk, NUVA is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs MGRM Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MGRM has a market cap of 207.2M. Regarding current trading prices, NUVA is priced at $39.75, while MGRM trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MGRM's P/E ratio is -11.46. In terms of profitability, NUVA's ROE is +0.05%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, NUVA is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs BSGM Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSGM has a market cap of 187.8M. Regarding current trading prices, NUVA is priced at $39.75, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSGM's P/E ratio is -11.51. In terms of profitability, NUVA's ROE is +0.05%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, NUVA is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs SGHT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SGHT has a market cap of 184.6M. Regarding current trading prices, NUVA is priced at $39.75, while SGHT trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SGHT's P/E ratio is -3.64. In terms of profitability, NUVA's ROE is +0.05%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, NUVA is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs PROF Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PROF has a market cap of 174.3M. Regarding current trading prices, NUVA is priced at $39.75, while PROF trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PROF's P/E ratio is -4.79. In terms of profitability, NUVA's ROE is +0.05%, compared to PROF's ROE of -0.70%. Regarding short-term risk, NUVA is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs TLSI Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TLSI has a market cap of 170.9M. Regarding current trading prices, NUVA is priced at $39.75, while TLSI trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TLSI's P/E ratio is -4.09. In terms of profitability, NUVA's ROE is +0.05%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, NUVA is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs INGN Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INGN has a market cap of 170.5M. Regarding current trading prices, NUVA is priced at $39.75, while INGN trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INGN's P/E ratio is -5.51. In terms of profitability, NUVA's ROE is +0.05%, compared to INGN's ROE of -0.15%. Regarding short-term risk, NUVA is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs RPID Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RPID has a market cap of 161.3M. Regarding current trading prices, NUVA is priced at $39.75, while RPID trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RPID's P/E ratio is -3.57. In terms of profitability, NUVA's ROE is +0.05%, compared to RPID's ROE of -0.56%. Regarding short-term risk, NUVA is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs ANIK Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ANIK has a market cap of 157.3M. Regarding current trading prices, NUVA is priced at $39.75, while ANIK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ANIK's P/E ratio is -14.63. In terms of profitability, NUVA's ROE is +0.05%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, NUVA is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs ELMD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ELMD has a market cap of 157.2M. Regarding current trading prices, NUVA is priced at $39.75, while ELMD trades at $18.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ELMD's P/E ratio is 23.73. In terms of profitability, NUVA's ROE is +0.05%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, NUVA is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs LNSR Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LNSR has a market cap of 155.6M. Regarding current trading prices, NUVA is priced at $39.75, while LNSR trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LNSR's P/E ratio is -2.69. In terms of profitability, NUVA's ROE is +0.05%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, NUVA is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs RCEL Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RCEL has a market cap of 153.6M. Regarding current trading prices, NUVA is priced at $39.75, while RCEL trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RCEL's P/E ratio is -2.65. In terms of profitability, NUVA's ROE is +0.05%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, NUVA is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs OWLT Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, OWLT has a market cap of 135.8M. Regarding current trading prices, NUVA is priced at $39.75, while OWLT trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas OWLT's P/E ratio is -5.10. In terms of profitability, NUVA's ROE is +0.05%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, NUVA is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs LUNG Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LUNG has a market cap of 130.4M. Regarding current trading prices, NUVA is priced at $39.75, while LUNG trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LUNG's P/E ratio is -2.25. In terms of profitability, NUVA's ROE is +0.05%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, NUVA is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs LUCD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LUCD has a market cap of 121.2M. Regarding current trading prices, NUVA is priced at $39.75, while LUCD trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LUCD's P/E ratio is -0.96. In terms of profitability, NUVA's ROE is +0.05%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, NUVA is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs AVR Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AVR has a market cap of 118.6M. Regarding current trading prices, NUVA is priced at $39.75, while AVR trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AVR's P/E ratio is -0.92. In terms of profitability, NUVA's ROE is +0.05%, compared to AVR's ROE of -2.92%. Regarding short-term risk, NUVA is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.
NUVA vs ICAD Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NUVA is priced at $39.75, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NUVA's ROE is +0.05%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, NUVA is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs FONR Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, FONR has a market cap of 99M. Regarding current trading prices, NUVA is priced at $39.75, while FONR trades at $15.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas FONR's P/E ratio is 12.77. In terms of profitability, NUVA's ROE is +0.05%, compared to FONR's ROE of +0.09%. Regarding short-term risk, NUVA is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.
NUVA vs HJLI Comparison
NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NUVA is priced at $39.75, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas HJLI's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, NUVA is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.